Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2022-06-30 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Closure of trading window
Regulatory Filings Classification · 100% confidence The document text is extremely short (123 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, report title, regulatory references, or any textual information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2022-06-30 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a transcript of a conference call held on June 6, 2022, discussing the quarterly and financial year ended March 31, 2022 results. It includes detailed discussions by company executives about financial performance, product updates, market conditions, and Q&A with analysts. The text explicitly mentions it is a transcript of the earnings conference call, which is a typical format for Call Transcripts (CT). The document contains detailed spoken content rather than a summary or announcement, and it is not a formal earnings release or annual/interim report. Therefore, the appropriate classification is Call Transcript (CT).
2022-06-09 English
Related Party Transaction
Regulatory Filings
2022-06-07 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the audio recording of an Analysts/Investors Conference Call about the financial results for the quarter and year ended March 31, 2022. It references the conference call and provides a link to the audio recording, indicating it is an announcement related to the call rather than the call transcript itself. The document length is short (1358 characters), and it does not contain the full transcript text. Therefore, it is not the full Call Transcript (CT) but rather an announcement about the call recording. However, since the document specifically mentions the conference call and the audio recording, the closest classification is Call Transcript (CT), as it pertains directly to the conference call event and its content. Confidence is high due to explicit mention of the conference call and financial results discussion.
2022-06-06 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 95% confidence The document is an invitation to a conference call discussing the financial performance for the quarter and financial year ended March 31, 2022. It includes details about the date, time, dial-in numbers, and participants. There is no actual financial data or report content included, only an announcement of the call event. Therefore, this document is best classified as a Call Transcript (CT) category, specifically an invitation or announcement related to a conference call.
2022-06-02 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation on Q4 & FY 2022 Financial Results' and is addressed to stock exchanges referencing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. It contains detailed company overview, strategic focus, financial highlights, manufacturing facilities, R&D, and management team information. The content is consistent with a presentation aimed at investors summarizing quarterly and annual financial results and company strategy. It is not a full annual report or audit report, nor is it a brief earnings release or a regulatory filing. The document length is substantial (15,000 characters) and contains detailed slides and data typical of an investor presentation. Therefore, the appropriate classification is Investor Presentation (IP).
2022-06-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.